Oxford, England – The latest data from human experiments showThe vaccine, developed by Oxford University and British pharmaceutical giant AstraZeneca, is safe and, most importantly, works well for the most vulnerable groups of patients.
Peer-reviewed evidence published in The Lancet on Thursday was reviewednot only does it trigger the strong immune response they had hoped for, but it contains a powerful blow where it is most needed: in older adults.
Ongoing trials have found that the vaccine is actually even better tolerated in older people than in younger people.
For the analysis, published on Thursday, external researchers studied Oxford̵
“The strong antibody and T cell responses observed in older adults in our study are encouraging,” said Dr. Maheshi Ramazami of Oxford University, co-author of The Lancet. “We hope this means that our vaccine will help protect some of the most vulnerable people in society, but more research will be needed before we are sure.”
Good news announced last weekand regarding their vaccines, which are even further down the road from testing and will soon apply to the US government for an emergency use permit, there has been a boost for the Oxford vaccine, as these vaccines use a similar approach. All three vaccines focus on the protein of the new coronavirus, which allows it to attach to human cells, thus causing infection.
While the Oxford team uses a different biochemical process, the goal is the same: All three vaccines aim to trick the body into building an immune response that remembers this particular coronavirus in case it attacks to prevent it from attaching to cells.
How long this immune response will last is not yet entirely clear, but researchers are increasingly optimistic that vaccines will remain effective for up to a year, if not longer, after the recommended dose.
The Oxford team said on Thursday that although the tests had not yet proven effective, as Pfizer and Moderna had announced, they were “satisfied” with the results and hoped to have their own Phase 3 data to speed it up with the rest. in the coming weeks.
Oxford’s chief researcher for vaccines, Professor Andrew Pollard, said the news was encouraging, but “we are in no hurry”.
He insisted that Oxford and AstraZeneca “are not in competition with other developers – what we are trying to do is make sure we have very high quality data … when they are ready, then we will provide interim results.”